Holen Sie sich die Stockscreener-App
18.88
0.63%
-0.12
Handel nachbörslich:
18.88
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio’s (ANAB) “Outperform” Rating Reiterated at Wedbush - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Yahoo Finance
JPMorgan Chase & Co. Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
(ANAB) Proactive Strategies - Stock Traders Daily
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) - MSN
Leerink Partnrs Lifts Earnings Estimates for AnaptysBio - Defense World
What is Wedbush’s Forecast for AnaptysBio FY2024 Earnings? - Defense World
FY2024 EPS Estimates for AnaptysBio Lifted by HC Wainwright - Defense World
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
What is Wedbush's Forecast for AnaptysBio FY2024 Earnings? - MarketBeat
HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Earns “Outperform” Rating from Wedbush - Defense World
Lilly bid wilts as others forge on with PD-1 in RA - BioWorld Online
AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet - Simply Wall St
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - Defense World
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates - MSN
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Earnings Beat - MarketBeat
AnaptysBio shares hold Outperform rating; Leerink notes strong cash position and clinical progress - Investing.com UK
AnaptysBio stock target cut on increased expenses By Investing.com - Investing.com Canada
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright - StreetInsider.com
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners - StreetInsider.com
AnaptysBio Inc (ANAB) Q3 2024 Earnings: Revenue Soars to $30M, E - GuruFocus.com
AnaptysBio Reports Q3 2024 Financial Results and Updates - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c - StreetInsider.com
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Anaptys Announces Participation in November and December Investor Conferences - The Manila Times
AnaptysBio's Q3 Revenue Surges to $30M, Cash Position Hits $458M Ahead of Key Trial Data | ANAB Stock News - StockTitan
AnaptysBio CEO to Present at 4 Major Healthcare Conferences Through Year-End | ANAB Stock News - StockTitan
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4%Here's What Happened - MarketBeat
Things To Consider Before Buying AnaptysBio Inc (NASDAQ: ANAB) - Stocks Register
AnaptysBio: Too Risky, Especially After LLY Drops Its Related Programs - Seeking Alpha
AnaptysBio (ANAB) Shares Plunge as Eli Lilly Ends Arthritis Drug Research - GuruFocus.com
AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright - MarketBeat
(ANAB) Trading Advice - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Gap DownHere's What Happened - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $33.00 - MarketBeat
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
AnaptysBio stock falls as Lilly updates pipeline (ANAB:NASDAQ) - Seeking Alpha
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - TradingView
Assenagon Asset Management S.A. Grows Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 6.9%Here's Why - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from Analysts - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 - Defense World
nVerses Capital LLC Buys 1,400 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Guggenheim reiterates buy rating on AnaptysBio stock, sees favorable risk/reward ahead of December readout - Investing.com Canada
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts - Benzinga
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 at Guggenheim - MarketBeat
(ANAB) On The My Stocks Page - Stock Traders Daily
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):